MarketWired describes JeanMarie Guenot as a renowned expert in the pharmaceutical and biotechnology industry. For over two decades, she has rendered her services for different companies. Guenot has worked for both private and public companies. She has extensive experience in corporate and commercial development, pharmaceutical R&D, and project & alliance management. JeanMarie has adequate skills in business development and venture capital. Guenot has developed a deep passion for building and redeveloping firms. Presently, she serves as the president and CEO of Amphivena Therapeutics, Inc. This corporation creates innovative bi-functional antibody therapies for hematologic malignancies.
Before JeanMarie started working for Amphivena, JeanMarie served as the CEO of SKS Ocular. She is the founder of the organization. This ophthalmic firm specialized on dry AMD. It engaged in the manufacture of ocular drug technologies and therapeutics for macular degeneration, glaucoma, and ocular inflammation. Additionally, Guenot worked as a business advisor for Hoffman-La Roche in Basel and Shanghai. She was also PDL BioPharma’s vice president of corporate and business development. At the firm, she oversaw mergers and acquisitions, licensing, as well as alliance management for the company’s R&D and commercial product portfolios.
JeanMarie Guenot negotiated and succeeded in closing the Biogen Idec-PDL 50:50 deal. Based on this agreement, the two companies engaged in the co-development and co-commercialization of a cancer drug. This collaboration involved three phase 2 cancer drug candidates. The $800 million transaction comprised of a $100 million equity investment in PDL as well as a therapeutic candidate. Ophthalmic indication, which was licensed by JeanMarie, was split between Hoffman-La Roche and Biogen Idec. She has alliance, portfolio, and project management experience in the fields of cardiovascular disease, oncology, and neurology. In addition, JeanMarie is well versed in autoimmune diseases and ophthalmic diseases.
JeanMarie Guenot started her business career at Atlas Venture. In this company, she developed life science firms and managed venture capital investments. In her scientific profession, Guenot started as the Preclinical R&D chief scientist at Hoffman-La Roche. She was responsible for manufacturing drugs for inflammation and metabolic diseases. Guenot earned her PhD from the renowned University of California, San Francisco. Additionally, she holds a Masters of Business Administration degree from the University of Pennsylvania’s Wharton School.